CD274 and neoplasm: For patients with baseline tumor PD-L1 levels less than 1%, the pooled outcome favored neoadjuvant chemoimmunotherapy (HR, 0.74; 95% CI, 0.62-0.89; I2 = 0%) (Figure 2).